Marco Hofmann

26 posts

Marco Hofmann

@MarcoHHofmann

biologist, scientist, drug-hunter, oncology research

Katılım Ekim 2019

139 Takip Edilen149 Takipçiler

Marco Hofmann retweetledi

Norbert Kraut@norbertkraut1·5 Ağu

Out now in @NatureCancer. Our brand-new paper shows co-targeting of KRASG12C plus SOS1 as strategy for treating KRAS-G12C inhibitor-naïve and relapsed mutant tumors. Thanks to @MDAndersonNews, @timheff5 and team and congrats to the @Boehringer #KRAS team nature.com/articles/s4301…

English

6.2K

Marco Hofmann retweetledi

Norbert Kraut@norbertkraut1·18 Nis

Thanks for including our paper published in @CD_AACR describing BI-3406, a potent and selective SOS1-KRAS interaction inhibitor. aacrjournals.org/cancerdiscover… @MarcoHHofmann @D_B_McConnell @Real_Dr_Kessler @gerlach_d @timheff5 #KRAS #AACR23

Cancer Discovery@CD_AACR

Attending #AACR23? Pick up a copy of the 'Best of the @AACR Journals' in booth 2743! bit.ly/3HefxYH

English

3.3K

Marco Hofmann retweetledi

Elizabeth McKenna@ElizSMcKenna·15 Nis

#AACR23: For more on Beating #KRAS, don't miss this @CD_AACR review - Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants @MarcoHHofmann @gerlach_d @Sandra_Misale @norbertkraut1 aacrjournals.org/cancerdiscover…

English

32.9K

Marco Hofmann retweetledi

Anna Obenauf@obenaufa·21 Şub

Looking forward to an exciting program of the @EACRnews @Boehringer virtual conference "Drugging and Regulating the MAP Kinase Pathway" co-organized with #ReneBernards @msmelanoma @MarcoHHofmann @Ralph_A_N So many developments in this field and challenges we need to tackle!

English

7.9K

Marco Hofmann retweetledi

Molecular Oncology@MolOncology·21 Şub

The first session of #eacrMAPKpathway is underway with @MarcoHHofmann @Boehringer introducing the interplay between inhibitors of SOS1 and KRAS Combination with SOS1i overcomes induced resistance to KRAS-G12Ci Does the upregulation of MRAS and RASGRP1 help explain resistance?

English

4.2K

Marco Hofmann retweetledi

venu☘️@itsvenu_·24 Oca

Check out our work on KRAS G12Ci + KRAS::SOS1i as a viable combination therapy to address KRAS G12Ci resistance. This work is the result of @Boehringer & @MDAndersonNews partnership. #KRAS @gerlach_d @norbertkraut1 @MarcoHHofmann @KRASKickers biorxiv.org/content/10.110…

English

6.8K

Marco Hofmann retweetledi

Daniel Gerlach@gerlach_d·24 Oca

Combined KRAS G12Ci + KRAS::SOS1i inhibition overcomes acquired resistance in Adagrasib-resistance CRC models - new pre-print from the @Boehringer and @MDAndersonNews partnership by @itsvenu_, Hengyu Lu and @MarcoHHofmann #KRAS #BI3406 #First4Patients doi.org/10.1101/2023.0…

English

7.1K

Marco Hofmann retweetledi

Anirban Maitra@Aiims1742·31 Ara

One of the best reviews this year on pharmacological targeting of KRAS - direct or indirect - is written by @norbertkraut1 @Sandra_Misale @gerlach_d @MarcoHHofmann in @CD_AACR - #OpenAccess & worth reading! aacrjournals.org/cancerdiscover…

English

3.6K

Marco Hofmann retweetledi

Daniel Gerlach@gerlach_d·11 Kas

🗓️Virtual conference upcoming "EACR-Boehringer Ingelheim Drugging and Regulating the MAP Kinase Pathway" with a great line-up of speakers. Join on February 21-22, 2023 to get the latest updates in the field. Registration: eacr.org/conference/boe… @EACRnews @Boehringer

English

Marco Hofmann retweetledi

Boehringer Ingelheim@Boehringer·21 Oca

#RESEARCHERS: Our scientists foresee a concept of two potential future classes of #KRAS medicines - just published in @CD_AACR! 👉 bit.ly/3nL3acD

English

Marco Hofmann retweetledi

Cancer Discovery@CD_AACR·19 Oca

Just published: A Review on Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants. bit.ly/33Nj7YI @norbertkraut1, @MarcoHHofmann, @gerlach_d, @Sandra_Misale, and Mark Petronczki

English

Marco Hofmann retweetledi

Daniel Gerlach@gerlach_d·19 Oca

📢Expanding the reach of precision🎯oncology by drugging all #KRAS mutants - our new review is out in @CD_AACR dx.doi.org/10.1158/2159-8…. Thanks to @MarcoHHofmann, @gerlach_d, @Sandra_Misale, Mark, and @norbertkraut1 #First4Patients #TakingCancerOn

English

103

Marco Hofmann retweetledi

Norbert Kraut@norbertkraut1·16 Eyl

Excited to partner with Amgen, combining our clinical-stage SOS1::pan-KRAS inhibitor with sotorasib, the first US FDA approved KRAS-G12C inhibitor. #KRAS #first4patients

Boehringer Ingelheim@Boehringer

#PRESS: We’re teaming up with Amgen to investigate the combination of our SOS1::pan-KRAS inhibitor with their #KRAS G12C inhibitor ➡ bit.ly/3hGnvNd

English

Marco Hofmann retweetledi

Vivek Subbiah, MD@VivekSubbiah·14 Nis

🚨⭐️MD Anderson & Boehringer Ingelheim have expanded their joint Virtual Research & Development Center to accelerate the development of new targeted therapies against KRAS and TRAILR2 in lung cancer @timheff5 #AACR21 @MDAndersonNews @boehringerus app.bronto.com/public/?q=prev…

English

Marco Hofmann retweetledi

Norbert Kraut@norbertkraut1·14 Nis

Great collaboration with @timheff5 and team at @MDAndersonNews Check out our joint presentations #AACR21 #KRAS #first4patients @D_B_McConnell @MarcoHHofmann @gerlach_d @DraettaG @joemarszalek

Boehringer Ingelheim@Boehringer

#PRESS: We are expanding our collaboration with @MDAndersonNews, reinforcing our dedication to finding solutions for people living with #LungCancer bit.ly/32dN9Ro #TakingCancerOn

English

Marco Hofmann retweetledi

Dirk Kessler@Real_Dr_Kessler·15 Mar

So exited to share our latest paper on SOS1 and the Discovery of BI-3406. Switching from a fluorine to a chlorine makes an inhibitor out of an activator. One Atom Makes All the Difference! @D_B_McConnell @ACSBioMed pubs.acs.org/doi/10.1021/ac…

English

Marco Hofmann retweetledi

Daniel Gerlach@gerlach_d·6 Oca

Our work on a novel small-molecule drug, the SOS1::KRAS inhibitor BI-3406, which targets KRAS-addicted cancers, is now published & formatted in the January 2021 issue of Cancer Discovery @CD_AACR - cancerdiscovery.aacrjournals.org/content/candis… @MarcoHHofmann @norbertkraut1 @timheff5 @Boehringer

English

Marco Hofmann retweetledi

Boehringer Ingelheim@Boehringer·17 Eyl

#PRESS: We’re teaming up with @MiratiTx to investigate the combination of our SOS1::pan-KRAS inhibitor with their #KRAS G12C selective inhibitor ➡ bit.ly/2FG54IF

English

Marco Hofmann retweetledi

Darryl B McConnell@D_B_McConnell·17 Eyl

Exciting news on Boehringer collaborating with Mirati on KRAS. Combining our SOS1 inhibitor with Mirati's KRAS-G12C in the clinic. boehringer-ingelheim.us/press-release/…

English